COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,822 Articles (22,968 medRxiv, 8,854 bioRxiv)

Most recent first Previous |  Page 1584: Articles 15831-15840  | Next

SARS-CoV-2 R.1 lineage variants prevailed in Tokyo in March 2021
Nagano, K., Tani-Sassa, C., Iwasaki, Y., Takatsuki, Y., Yuasa, S., Takahashi, Y., Nakajima, J., Sonobe, K., Ichimura, N., Nukui, Y., Takeuchi, H., Tanimoto, K., Tanaka, Y., Kimura, A., Tohda, S.
10.1101/2021.05.11.21257004 — Posted: 2021-05-17
Dear Watch, Should I Get a COVID-19 Test? Designing deployable machine learning for wearables
Nestor, B., Hunter, J., Kainkaryam, R., Drysdale, E., Inglis, J. B., Shapiro, A., Nagaraj, S., Ghassemi, M., Foschini, L., Goldenberg, A.
10.1101/2021.05.11.21257052 — Posted: 2021-05-17
Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older
Gobeil, P., Pillet, S., Seguin, A., Boulay, I., Mahmood, A., Vinh, D. C., Charland, N., Boutet, P., Roman, F. P., Van Der Most, R., de los Angeles Ceregido Perez, M., Ward, B. J., Landry, N.
10.1101/2021.05.14.21257248 — Posted: 2021-05-17 Discussion: Onsite
Extended interval BNT162b2 vaccination enhances peak antibody generation in older people
Parry, H. M., Bruton, R., Stephens, C., Brown, K., Amirthalingam, G., Hallis, B., Otter, A., Zuo, J., Moss, P.
10.1101/2021.05.15.21257017 — Posted: 2021-05-17 Discussion: Onsite
Pan-ErbB inhibition protects from SARS-CoV-2 replication, inflammation, and injury
Saul, S., Karim, M., Huang, P. T., Ghita, L., Chiu, W., Kumar, S., Bhalla, N., Leyssen, P., Cohen, C. A., Huie, K. E., Tindle, C., Sahoo, M. K., Sibai, M., Pinsky, B. A., Das, S., Ghosh, P., Dye, J., Solow-Cordero, D. E., Jin, J., Jochmans, D., Neyts, J., Narayanan, A., De Jonghe, S., Einav, S.
10.1101/2021.05.15.444128 — Posted: 2021-05-16
Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K.-L., Fiala, B., Murphy, M., Pettie, D., Kraft, J. C., Malone, K. D., Navarro, M. J., Ogohara, C., Kepl, E., Ravichandran, R., Sydeman, C., Ahlrichs, M., Johnson, M., Blackstone, A., Carter, L., Starr, T. N., Greaney, A. J., Lee, K. K., Veesler, D., Bloom, J. D., King, N. P.
10.1101/2021.05.15.444222 — Posted: 2021-05-16
Allicin inhibits SARS-CoV-2 replication and abrogates the antiviral host response in the Calu-3 proteome
Mösbauer, K., Fritsch, V. N., Adrian, L., Bernhardt, J., Gruhlke, M. C. H., Slusarenko, A. J., Niemeyer, D., Antelmann, H.
10.1101/2021.05.15.444275 — Posted: 2021-05-16
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R.
10.1101/2021.05.14.444076 — Posted: 2021-05-16
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
Pegu, A., O'Connell, S. E., Schmidt, S. D., O'Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K., Flach, B., Jackson, L., Leav, B., Ledgerwood, J. E., Luke, C. J., Makowski, M., Roberts, P. C., Roederer, M., Rebolledo, P. A., Rostad, C. A., Rouphael, N. G., Shi, W., Wang, L., Widge, A. T., Yang, E. S., Beigel, J. H., Graham, B. S., Mascola, J. R., Suthar, M. S., McDermott, A., Doria-Rose, N. A.
10.1101/2021.05.13.444010 — Posted: 2021-05-16
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition
Kramer, K. J., Johnson, N. V., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Holt, C. M., Hsieh, C.-L., Sutton, R. E., Paulo, A., Davidson, E., Doranz, B. J., Crowe, J. E., Bukreyev, A., Carnahan, R. H., McLellan, J. S., Georgiev, I. S.
10.1101/2021.05.16.444004 — Posted: 2021-05-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).